ArticleJournal of the American Board of Family Medicine : JABFM
Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Time to de-implementation of low-value cancer screening practices: a narrative review.BMJ quality & safety · 2025Review
- Chronological Trends of PSA Levels at Diagnosis in Population-based Prostate Cancer Data 2004-2021, a Time Period of Drastic Changes in Screening Guidelines: Potential Implications in Prostate Cancer Diagnosis.Journal of registry management · 2025Article
- Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study.Translational andrology and urology · 2024Article
- Prostate cancer epidemiology and prognostic factors in the United States.Frontiers in oncology · 2023Article
- Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations.BMC urology · 2022Article
- Trends in Incidence of Metastatic Prostate Cancer in the US.JAMA network open · 2022Article
- Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.JAMA network open · 2021Article
- Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.Cancer reports (Hoboken, N.J.) · 2021Article
- Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.Cancer reports (Hoboken, N.J.) · 2021Article
- Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.Journal of community health · 2021Article
- Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.Journal of general internal medicine · 2020Observational
- Trends in Cancer Incidence Among American Indians and Alaska Natives and Non-Hispanic Whites in the United States, 1999-2015.Epidemiology (Cambridge, Mass.) · 2020Article
- Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men.American journal of preventive medicine · 2018Article
- Prevalence of and factors associated with mammography and prostate-specific antigen screening among World Trade Center Health Registry enrollees, 2015-2016.Preventive medicine reports · 2018Article
- Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.Annals of epidemiology · 2018Article
- Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.The Journal of urology · 2018Article
- Engaging the primary care community to encourage appropriate prostate cancer screening.Therapeutic advances in urology · 2018Article
- Prostate Cancer Screening Trends After United States Preventative Services Task Force Guidelines in an Underserved Population.Health equity · 2018Article
- Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005-2015.American journal of preventive medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo assess changes of prostate-specific antigen (PSA) testing following recent US Preventive Services Task Force (USPSTF) prostate cancer screening recommendations using 2005 to 2013 National Health Interview Survey data.
methodsWe calculated the percentage of PSA testing among men ≥40 years by age group and age-adjusted race for each survey year. Differences between years were assessed with linear contrasts after combining all years' data.
resultsThe overall percentage of PSA testing was highest in 2008 and decreased significantly in 2013. Compared with 2008, each age group had significantly lower screening percentages in 2013, especially men ≥75 years old (-14.0% points; P < .001). Both men aged 50 to 74 and men aged ≥75 had significantly lower percentages in 2013 than in 2010. For white and black men, the PSA testing percentages were highest in 2008 and decreased significantly in 2013. Only white men had a significantly lower percentage in 2013 than in 2010.
conclusionsSignificant declines in PSA testing from 2008 to 2013 in men ≥75 years old may reflect the impact of the 2008 USPSTF recommendations. While the cause of the decreases in PSA testing between 2010 and 2013 among men aged 50 to 74 years old and white men is unknown, the decreases may suggest the early effects of the 2012 recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.